FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act

H.R. 5: All provisions of the Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011; H.R. 1409: All provisions of the Quality Health Care Coalition Act of 2011; H.R. 891/S. 274: All provisions of the Medication Therapy Management Benefits Act of 2011; H.R. 905 /S. 733: All provisions of the legislation to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare; H.R. 979 - All provisions of the FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 4 /S.18 / S.72 - All provisions of the Small Business Paperwork Mandate Elimination Act H.R. 605 / S. 312 - All provisions of the Patients Freedom to Choose Act S. 27 - All provisions of the Preserve Access to Affordable Generics Act S. 31 - All provisions of the Prescription Drug and Health Improvement Act of 2011 S. 44 - All provisions of the Medicare Prescription Drug Price Negotiation Act of 2011 H.R. 999 / S. 560 - All provisions of the Medicare Prescription Drug Savings and Choice Act of 2011 H.R. 1839 - All provisions of the Community Pharmacy Fairness Act of 2011; H.R. 1946 - All provisions of the Preserving or Hometown Independent Pharmacies Act of 2011; H.R. 1971 / S. 1058 - All provisions of the Pharmacy Competition and Consumer Choice Act of 2011 Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio) Regulatory and proposed legislative changes to Medicare part D including EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs Regulatory Implementation of the HITECH Act FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs), implementation of approval pathway for generic biologic drugs 340b program H.R. 2245/S. 296 - All provisions of the Preserving Access to Life-Saving Medications Act of 2011

Client expense: $559,998 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), SENATE

H.R. 979, The FEHBP Prescription Drug, Integrity, Transparency and Cost Savings Act. Postal Reform

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) - FEHBP prescription drugs, H.R.1946, Preserving Hometown Independent Pharmacies Act (Marino) - antitrust exemption for independent pharmacies, H.R. 3995, Protecting Consumer Access to Generic Drugs Act (Rush) - pay-for-delay settlements, S. 27, Preserve Access to Affordable Generics Act (Kohl) - pay-for-delay settlements, S. 2002, Online Pharmacy Safety Act (Feinstein) - establishes standards for on-line pharmacies, S. 2193, Ensuring Safe Medical Devices for Patients (Merkley) - FDA oversight of medical devices, S. 3187, the FDA Safety and Innovation Act (Harkin) - pharmaceutical, medical device issues.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) FEHBP prescription drugs 16. Specific Lobbying Issues (continued): H.R.1946, Preserving Hometown Independent Pharmacies Act (Marino) antitrust exemption for independent pharmacies H.R. 3995, Protecting Consumer Access to Generic Drugs Act (Rush) pay-for-delay settlements S. 27, Preserve Access to Affordable Generics Act (Kohl) pay-for-delay settlements S. 2002, Online Pharmacy Safety Act (Feinstein) establishes standards for on-line pharmacies S. 2193, Ensuring Safe Medical Devices for Patients (Merkley) FDA oversight of medical devices S. 3187, the FDA Safety and Innovation Act (Harkin) pharmaceutical, medical device issues Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to access for investigational drugs; and other issues relating to health care reform implementation.

Client expense: $2,020,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Federal Bureau of Investigation (FBI), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Office of Personnel Management (OPM), Pension & Welfare Benefits Administration, SENATE, Treasury, Dept of, White House Office

Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse. General issues dealing with pharmacy drug compounding.

Client expense: $630,728 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, White House Office

Issues related to Medicare Part D and anti-PBM legislation. Other issues include health care delivery system reforms, cost containment, medication adherence, restrictions on PBM cost saving tools like mail order, generics and restrictions on PBM audit practices. HR 979 - FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act S 1058 Pharmacy Competition and Consumer Choice HR 1971 Pharmacy Competition and Consumer Choice HR 4215-Medicare Pharmacy Transparency & Fair Auditing Act

Client expense: $2,930,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office

H.R.979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act.

Client expense: $70,000 · Firm income: Not reported

Government targets: Federal Aviation Administration (FAA), HOUSE OF REPRESENTATIVES, SENATE, Transportation, Dept of (DOT)

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 2746 - legislation that would require cost-sharing parity between all cancer medication within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payments/co-insurance rate for non-preferred brand drugs; HR 1971/S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans; HR 6584 - legislation that would impose federal requirements on compounding pharmacies

Client expense: $170,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 27, Preserve Access to Affordable Generics Act S. 31, Prescription Drug and Health Improvement Act of 2011 S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011 H.R. 147, Prescription Drug Affordability Act H.R. 741, To amend the Federal Food, Drug and Cosmetic Act to prohibit the marketing of authorized generic drugs H.R. 979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 1971, Pharmacy Competition and consumer Choice Act of 2011 H.R. 2128, STEAM (Stripping the E-Prescribe Arbitrary Mandates) Act of 2011 S. 1058, Pharmacy Competition and Consumer Act of 2011 S. 1356, Affordable Medicines Utilization Act of 2011 S. 1584, Drug Safety and Accountability Act of 2011 H.R. 3026, Safeguarding America's Pharmaceuticals Act of 2011 S. 2002, To amend the Federal Food, Drug, and Cosmetic Act to improve the safety of Internet Pharmacies S. 3187, FDA Safety and Innovation Act

Client expense: $440,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Federal Reserve System, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Justice, Dept of (DOJ), SENATE

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency, and Cost Saving Act H.R. 3485, Domestic Partner Benefits and Obligations Act S. 1910, Domestic Partner Benefits and Obligations Act S. 2196, Congressional Health Care for Seniors Act of 2012 S. 1058, Pharmacy Competition and Consumer Choice Act of 2011 H.R. 1971, Pharmacy Competition and Consumer Choice Act of 2011

Client expense: $193,305 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Defense, Dept of (DOD), Environmental Protection Agency (EPA), Federal Deposit Insurance Corporation (FDIC), Federal Election Commission (FEC), Food & Drug Administration (FDA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), Office of Management & Budget (OMB), Office of Personnel Management (OPM), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of, U.S. Customs & Border Protection

HR3844 S1323 HR270 HR408 S178 S644 HR1248 HR1470 HR122 HR828 HR1540 HR1297 HR979 S1936 HR48 S772 S991 HR342 HR327 HR567 HR616 HR2114 HR 1019 HR917 HR875 HR122 HR826 HR087 HR805 HR657 HR538 HR429 HR334 HR293 HR235 HR226 HR119 S514 S439 S376 S355 S300 S47 S261 HR3855 S2079 HR2196 S178 Sequestration S2065 HR3662 HR3844 S1651 S1476 FY13 Presidential Budget 2010 Simpson-Bowels Commission Proposal

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to Medicare Part D and anti-PBM legislation. H.R.979, FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act; S.1058/H.R. 1971, Pharmacy Competition and Consumer Choice; H.R. 4215, Medicare Pharmacy Transparency & Fair Auditing Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1409: All provisions of the Quality Health Care Coalition Act of 2011; H.R. 891/S. 274: All provisions of the Medication Therapy Management Benefits Act of 2011; H.R. 905 /S. 733:All provisions of the legislation to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare; H.R. 979 - All provisions of the FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 605 / S. 312 -All provisions of the Patients Freedom to Choose Act S. 27 - All provisions of the Preserve Access to Affordable Generics Act S. 31 - All provisions of the Prescription Drug and Health Improvement Act of 2011 S. 44 -All provisions of the Medicare Prescription Drug Price Negotiation Act of 2011 H.R. 999 / S. 560 - All provisions of the Medicare Prescription Drug Savings and Choice Act of 2011 H.R. 1839 - All provisions of the Community Pharmacy Fairness Act of 2011; H.R. 1946 - All provisions of the Preserving or Hometown Independent Pharmacies Act of 2011; H.R. 1971 / S. 1058 - All provisions of the Pharmacy Competition and Consumer Choice Act of 2011 Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio) Regulatory and proposed legislative changes to Medicare part D including EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs); implementation of approval pathway for generic biologic drugs 340b program H.R. 2672 the Preserving Access to Orphan Drugs Act H.R. 2182 the Generating Antibiotic Incentives Now Act H.R. 3026 the Safeguarding Americas Pharmaceuticals Act H.R. 2746 the Cancer Drug Coverage Parity Act H.R.4215 - All provisions of the Medicare Pharmacy Transparency and Fair Auditing Act

Client expense: $518,430 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), SENATE

H.R. 5: All provisions of the Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011; H.R. 1409: All provisions of the Quality Health Care Coalition Act of 2011; H.R. 891/S. 274: All provisions of the Medication Therapy Management Benefits Act of 2011; H.R. 905 /S. 733: All provisions of the legislation to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare; H.R. 979 - All provisions of the FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 4 /S.18 / S.72 - All provisions of the Small Business Paperwork Mandate Elimination Act H.R. 605 / S. 312 - All provisions of the Patients Freedom to Choose Act S. 27 - All provisions of the Preserve Access to Affordable Generics Act S. 31 - All provisions of the Prescription Drug and Health Improvement Act of 2011 S. 44 - All provisions of the Medicare Prescription Drug Price Negotiation Act of 2011 H.R. 999 / S. 560 - All provisions of the Medicare Prescription Drug Savings and Choice Act of 2011 H.R. 1839 - All provisions of the Community Pharmacy Fairness Act of 2011; H.R. 1946 - All provisions of the Preserving or Hometown Independent Pharmacies Act of 2011; H.R. 1971 / S. 1058 - All provisions of the Pharmacy Competition and Consumer Choice Act of 2011 Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio) Regulatory and proposed legislative changes to Medicare part D including EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs Regulatory Implementation of the HITECH Act FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs), implementation of approval pathway for generic biologic drugs 340b program H.R. 2245/S. 296 - All provisions of the Preserving Access to Life-Saving Medications Act of 2011

Client expense: $518,430 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), SENATE

HR3844 S1323 HR270 HR408 S178 S644 HR1248 HR1470 HR122 HR828 HR1540 HR1297 HR979 S1936 HR48 S772 S991 HR342 HR327 HR567 HR616 HR2114 HR 1019 HR917 HR875 HR122 HR826 HR087 HR805 HR657 HR538 HR429 HR334 HR293 HR235 HR226 HR119 S514 S439 S376 S355 S300 S47 S261 HR3855 S2079 HR2196 S178 Sequestration S2065 HR3662 HR3844 S1651 S1476 FY13 Presidential Budget 2010 Simpson-Bowels Commission Proposal

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 979, The FEHBP Prescription Drug, Integrity, Transparency and Cost Savings Act. Postal Reform

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) - FEHBP prescription drugs. H.R.1946, Preserving Hometown Independent Pharmacies Act (Marino) - antitrust exemption for independent pharmacies. H.R. 3995, Protecting Consumer Access to Generic Drugs Act (Rush) - pay-for-delay settlements. S. 27, Preserve Access to Affordable Generics Act (Kohl) - pay-for-delay settlements. S. 2002, Online Pharmacy Safety Act (Feinstein) - establishes standards for on-line pharmacies. S. 2193, Ensuring Safe Medical Devices for Patients (Merkley) - FDA oversight of medical devices. S. 3187, the FDA Safety and Innovation Act (Harkin) - pharmaceutical, medical device issues.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act.

Client expense: $70,000 · Firm income: Not reported

Government targets: Federal Aviation Administration (FAA), HOUSE OF REPRESENTATIVES, SENATE, Transportation, Dept of (DOT)

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs. HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

Client expense: $170,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 27, Preserve Access to Affordable Generics Act S. 31, Prescription Drug and Health Improvement Act of 2011 S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011 H.R. 147, Prescription Drug Affordability Act H.R. 741, To amend the Federal Food, Drug and Cosmetic Act to prohibit the marketing of authorized generic drugs H.R. 979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 1971, Pharmacy Competition and consumer Choice Act of 2011 H.R. 2128, STEAM (Stripping the E-Prescribe Arbitrary Mandates) Act of 2011 S. 1058, Pharmacy Competition and Consumer Act of 2011 S. 1356, Affordable Medicines Utilization Act of 2011 S. 1584, Drug Safety and Accountability Act of 2011 H.R. 3026, Safeguarding America's Pharmaceuticals Act of 2011 S. 2002, To amend the Federal Food, Drug, and Cosmetic Act to improve the safety of Internet Pharmacies S. 3187, FDA Safety and Innovation Act

Client expense: $440,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Federal Reserve System, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Justice, Dept of (DOJ), SENATE

Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse

Client expense: $423,292 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, White House Office

H.R. 979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) FEHBP prescription drugs 16. Specific Lobbying Issues (continued): H.R.1946, Preserving Hometown Independent Pharmacies Act (Marino) antitrust exemption for independent pharmacies H.R. 3995, Protecting Consumer Access to Generic Drugs Act (Rush) pay-for-delay settlements S. 27, Preserve Access to Affordable Generics Act (Kohl) pay-for-delay settlements S. 2002, Online Pharmacy Safety Act (Feinstein) establishes standards for on-line pharmacies S. 2193, Ensuring Safe Medical Devices for Patients (Merkley) FDA oversight of medical devices S. 3187, the FDA Safety and Innovation Act (Harkin) pharmaceutical, medical device issues Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to access for investigational drugs; and other issues relating to health care reform implementation.

Client expense: $2,630,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Federal Bureau of Investigation (FBI), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Office of Personnel Management (OPM), Pension & Welfare Benefits Administration, SENATE, Treasury, Dept of, White House Office

Issues related to the corporate business model, Medicare Part D and anti-PBM legislation. Other issues include health care delivery system reforms, cost containment, medication adherence, restrictions on PBM cost saving tools like mail order, generics and restrictions on PBM audit practices. H.R.979, FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act; S.1058/H.R. 1971, Pharmacy Competition and Consumer Choice; H.R. 4215, Medicare Pharmacy Transparency & Fair Auditing Act.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office

Issues related to Medicare Part D and anti-PBM legislation. Other issues include health care delivery system reforms, cost containment, medication adherence, restrictions on PBM cost saving tools like mail order, generics and restrictions on PBM audit practices. HR 979 - FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act S 1058 Pharmacy Competition and Consumer Choice HR 1971 Pharmacy Competition and Consumer Choice HR 4215-Medicare Pharmacy Transparency & Fair Auditing Act

Client expense: $2,320,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency, and Cost Saving Act H.R. 3485, Domestic Partner Benefits and Obligations Act S. 1910, Domestic Partner Benefits and Obligations Act S. 2196, Congressional Health Care for Seniors Act of 2012 S. 1058, Pharmacy Competition and Consumer Choice Act of 2011 H.R. 1971, Pharmacy Competition and Consumer Choice Act of 2011

Client expense: $174,096 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Defense, Dept of (DOD), Environmental Protection Agency (EPA), Federal Deposit Insurance Corporation (FDIC), Federal Election Commission (FEC), Food & Drug Administration (FDA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), Office of Management & Budget (OMB), Office of Personnel Management (OPM), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of, U.S. Customs & Border Protection

SENATE FY13 BUDGET RESOLUTION; H. CON. RES. 112; HR 1; HR 7; HR 122; HR 235; HR 261; HR 270; HR 327; HR 408; HR 616; HR 657; HR 807; HR 828; HR 979; HR 1068; HR 1332; HR 1470; HR 1492; HR 1540; HR 1779; HR 2017; HR 2055; HR 2065; HR 2090; HR 2112; HR 2114; HR 2145; HR 2219; HR 2354; HR 2434; HR 2608; HR 3029; HR 3070; HR 3485; HR 3487; HR 3630; HR 3662; HR 3813; HR 3835; HR 3844; HR 4072; HR 4310; HR 4348; HR 5652; HR 5854; HR 5855; HR 5856; HR 6020; HR 6042; HR 6306; S 113; S 178; S 261; S 376; S 572; S 644; S 743; S 790; S 981; S 1143; S 1476; S 1573; S 1599; S 1611; S 1789; S 1813; S 1910; S 1936; S 2065; S 2079; S 2249; S 3175; S 3301; S 3481; S 3585

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

SENATE FY13 BUDGET RESOLUTION; H. CON. RES. 112; HR 1; HR 7; HR 122; HR 235; HR 261; HR 270; HR 327; HR 408; HR 616; HR 657; HR 807; HR 828; HR 979; HR 1068; HR 1332; HR 1470; HR 1492; HR 1540; HR 1779; HR 2017; HR 2055; HR 2065; HR 2090; HR 2112; HR 2114; HR 2145; HR 2219; HR 2354; HR 2434; HR 2608; HR 3029; HR 3070; HR 3485; HR 3487; HR 3630; HR 3662; HR 3813; HR 3835; HR 3844; HR 4072; HR 4310; HR 4348; HR 5652; HR 5854; HR 5855; HR 5856; HR 6020; HR 6042; HR 6306; S 113; S 178; S 261; S 376; S 572; S 644; S 743; S 790; S 981; S 1143; S 1476; S 1573; S 1599; S 1611; S 1789; S 1813; S 1910; S 1936; S 2065; S 2079; S 2249; S 3175; S 3301; S 3481; S 3585

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR3844 S1323 HR3630 HR270 HR408 S178 S644 HR1248 HR1470 HR122 HR828 HR1540 HR1297 HR979 S1936 HR48 S772 S991 HR342 HR327 HR567 HR616 HR2114 HR 1019 HR917 HR875 HR122 HR826 HR087 HR805 HR657 HR538 HR429 HR334 HR381 HR293 HR235 HR226 HR119 S514 S439 S376 S355 S300 S47 S261 HR3855 S2079 HR2196 S178 S206

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 979, The FEHBP Prescription Drug, Integrity, Transparency and Cost Savings Act. Postal Reform

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) FEHBP prescription drugs H.R.1946, Preserving Hometown Independent Pharmacies Act (Marino) antitrust exemption for independent pharmacies H.R. 3988, Generic Drug and Biosimilar User Fee Act (Murphy/Pitts/Waxman) FDA user fee programs 16. Specific Lobbying Issues (continued): H.R. 3995, Protecting Consumer Access to Generic Drugs Act (Rush) pay-for-delay settlements H.R. 5651, FDA Reform Act (Upton) pharmaceutical, medical device issues S. 27, Preserve Access to Affordable Generics Act (Kohl) pay-for-delay settlements S. 2193, Ensuring Safe Medical Devices for Patients (Merkley) FDA oversight of medical devices S. 2516, the FDA Safety and Innovation Act (Harkin) pharmaceutical, medical device issues S. 3187, the FDA Safety and Innovation Act (Harkin) pharmaceutical, medical device issues S. 2002, Online Pharmacy Safety Act (Feinstein) establishes standards for on-line pharmacies Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; and issues relating to access for investigational drugs; and other issues relating to health care reform implementation.

Client expense: $2,240,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Federal Bureau of Investigation (FBI), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Office of Personnel Management (OPM), Pension & Welfare Benefits Administration, SENATE, Treasury, Dept of, White House Office

Issues related to Medicare Part D and anti-PBM legislation. Other issues include health care delivery system reforms, cost containment, medication adherence, restrictions on PBM cost saving tools like mail order, generics and restrictions on PBM audit practices. HR 979 - FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act S 1058 Pharmacy Competition and Consumer Choice HR 1971 Pharmacy Competition and Consumer Choice HR 4215-Medicare Pharmacy Transparency & Fair Auditing Act

Client expense: $2,255,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

S. 27, Preserve Access to Affordable Generics Act S. 31, Prescription Drug and Health Improvement Act of 2011 S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011 H.R. 147, Prescription Drug Affordability Act H.R. 741, To amend the Federal Food, Drug and Cosmetic Act to prohibit the marketing of authorized generic drugs H.R. 979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 1971, Pharmacy Competition and consumer Choice Act of 2011 H.R. 2128, STEAM (Stripping the E-Prescribe Arbitrary Mandates) Act of 2011 S. 1058, Pharmacy Competition and Consumer Act of 2011 S. 1356, Affordable Medicines Utilization Act of 2011 S. 1584, Drug Safety and Accountability Act of 2011 H.R. 3026, Safeguarding America's Pharmaceuticals Act of 2011 S. 2002, To amend the Federal Food, Drug, and Cosmetic Act to improve the safety of Internet Pharmacies S. 3187, FDA Safety and Innovation Act

Client expense: $560,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Federal Reserve System, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Justice, Dept of (DOJ), SENATE

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 5651 and S 3187 - reauthorization of the prescription drug user fee act; S 296 and HR 2245 - legislation that would address shortages of prescription drugs; HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs. HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

Client expense: $150,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) - FEHBP prescription drugs H.R.1946, Preserving Hometown Independent Pharmacies Act (Marino) - antitrust exemption for independent pharmacies H.R. 3988, Generic Drug and Biosimilar User Fee Act (Murphy/Pitts/Waxman) - FDA user fee programs H.R. 3995, Protecting Consumer Access to Generic Drugs Act (Rush) - pay-for-delay settlements H.R. 5651, FDA Reform Act (Upton) - pharmaceutical, medical device issues S. 27, Preserve Access to Affordable Generics Act (Kohl) - pay-for-delay settlements S. 2193, Ensuring Safe Medical Devices for Patients (Merkley) - FDA oversight of medical devices S. 2516, the FDA Safety and Innovation Act (Harkin) - pharmaceutical, medical device issues S. 3187, the FDA Safety and Innovation Act (Harkin) - pharmaceutical, medical device issues S. 2002, Online Pharmacy Safety Act (Feinstein) - establishes standards for on-line pharmacies

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency, and Cost Saving Act H.R. 3485, Domestic Partner Benefits and Obligations Act S. 1910, Domestic Partner Benefits and Obligations Act S. 2196, Congressional Health Care for Seniors Act of 2012 S. 1058, Pharmacy Competition and Consumer Choice Act of 2011 H.R. 1971, Pharmacy Competition and Consumer Choice Act of 2011

Client expense: $201,821 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Defense, Dept of (DOD), Environmental Protection Agency (EPA), Federal Deposit Insurance Corporation (FDIC), Federal Election Commission (FEC), Food & Drug Administration (FDA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), Office of Management & Budget (OMB), Office of Personnel Management (OPM), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of, U.S. Customs & Border Protection

*FEHBP prescription drugs - HR 979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act. *Pay-for-delay settlements - S 27, Preserve Access to Affordable Generics Act. *Antitrust exemption for independent pharmacies - HR 1946, Preserving Our Hometown Independent Pharmacies Act of 2011. *FDA user fee programs - HR 3988, Generic Drug and Biosimilar User Fee Act of 2012. *Pay-for-delay settlements - HR 3995, Protecting Consumer Access to Generic Drugs Act of 2012. *FDA oversight of medical devices - S 2193, Ensuring Safe Medical Devices for Patients. *Pharmaceutical, medical device issues - HR 5651, Food and Drug Administration Reform Act of 2012; S 2516, Food and Drug Administration Safety and Innovation Act; S 3187, Food and Drug Administration Safety and Innovation Act. *Standards for on-line pharmacies - S 2002, Online Pharmacy Safety Act.

Client expense: Not reported · Firm income: $100,000

Government targets: HOUSE OF REPRESENTATIVES

H.R. 1409: All provisions of the Quality Health Care Coalition Act of 2011; H.R. 891/S. 274: All provisions of the Medication Therapy Management Benefits Act of 2011; H.R. 905 /S. 733:All provisions of the legislation to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare; H.R. 979 - All provisions of the FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 605 / S. 312 -All provisions of the Patients Freedom to Choose Act S. 27 - All provisions of the Preserve Access to Affordable Generics Act S. 31 - All provisions of the Prescription Drug and Health Improvement Act of 2011 S. 44 -All provisions of the Medicare Prescription Drug Price Negotiation Act of 2011 H.R. 999 / S. 560 - All provisions of the Medicare Prescription Drug Savings and Choice Act of 2011 H.R. 1839 - All provisions of the Community Pharmacy Fairness Act of 2011; H.R. 1946 - All provisions of the Preserving or Hometown Independent Pharmacies Act of 2011; H.R. 1971 / S. 1058 - All provisions of the Pharmacy Competition and Consumer Choice Act of 2011 Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio) Regulatory and proposed legislative changes to Medicare part D including EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs); implementation of approval pathway for generic biologic drugs 340b program H.R. 2672 the Preserving Access to Orphan Drugs Act H.R. 2182 the Generating Antibiotic Incentives Now Act H.R. 3026 the Safeguarding Americas Pharmaceuticals Act H.R. 2746 the Cancer Drug Coverage Parity Act H.R.4215 - All provisions of the Medicare Pharmacy Transparency and Fair Auditing Act

Client expense: $520,389 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), SENATE

H.R. 5: All provisions of the Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011; H.R. 1409: All provisions of the Quality Health Care Coalition Act of 2011; H.R. 891/S. 274: All provisions of the Medication Therapy Management Benefits Act of 2011; H.R. 905 /S. 733: All provisions of the legislation to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare; H.R. 979 - All provisions of the FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 4 /S.18 / S.72 - All provisions of the Small Business Paperwork Mandate Elimination Act H.R. 605 / S. 312 - All provisions of the Patients Freedom to Choose Act S. 27 - All provisions of the Preserve Access to Affordable Generics Act S. 31 - All provisions of the Prescription Drug and Health Improvement Act of 2011 S. 44 - All provisions of the Medicare Prescription Drug Price Negotiation Act of 2011 H.R. 999 / S. 560 - All provisions of the Medicare Prescription Drug Savings and Choice Act of 2011 H.R. 1839 - All provisions of the Community Pharmacy Fairness Act of 2011; H.R. 1946 - All provisions of the Preserving or Hometown Independent Pharmacies Act of 2011; H.R. 1971 / S. 1058 - All provisions of the Pharmacy Competition and Consumer Choice Act of 2011 Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio) Regulatory and proposed legislative changes to Medicare part D including EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs Regulatory Implementation of the HITECH Act FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs), implementation of approval pathway for generic biologic drugs 340b program H.R. 2245/S. 296 - All provisions of the Preserving Access to Life-Saving Medications Act of 2011

Client expense: $520,389 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), SENATE

Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).

Client expense: $470,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, White House Office

H.R.979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act.

Client expense: $60,000 · Firm income: Not reported

Government targets: Federal Aviation Administration (FAA), HOUSE OF REPRESENTATIVES, SENATE, Transportation, Dept of (DOT)

H.R. 979, The FEHBP Prescription Drug, Integrity, Transparency and Cost Savings Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Postal Service and 5-day mail delivery; HR 979, FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Health reform proposals that impact Medicare Part D; healthcare regulations; closing of the Part D coverage gap; IVIG payment structure; Medicar demonstration projects for durable medical equipment; home infusion; PBM disclosure provisions; increasing healthcare value; competitive bidding (H.R. 2195, S. 1203, H.R. 1845, S. 960, H.R. 979, H.R. 1041)

Client expense: $1,050,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058).

Client expense: $370,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, U.S. Trade Representative (USTR), White House Office

H.R. 979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) FEHBP prescription drugs H.R.1946, Preserving Hometown Independent Pharmacies Act (Marino) antitrust exemption for independent pharmacies H.R. 3988, Generic Drug and Biosimilar User Fee Act (Murphy/Pitts/Waxman) FDA user fee programs 16. Specific Lobbying Issues (continued): H.R. 3995, Protecting Consumer Access to Generic Drugs Act (Rush) pay-for-delay settlements S. 27, Preserve Access to Affordable Generics Act (Kohl) pay-for-delay settlements S. 2193, Ensuring Safe Medical Devices for Patients (Merkley) FDA oversight of medical devices H.R. 3209, Premarket Predictability Act (Shimkus) changes to the device process H.R. 3208, Patients Come First Act (Shimkus) - changes to the device process H.R. 3205, FDA Renewing Efficiency from Outside Review Management Act of 2011 (Paulsen) changes to the device process Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; and issues relating to access for investigational drugs. 18. Lobbyists (continued): K. Callahan: Ross (March 2005- January 2012); Research Assistant, Senator Tim Johnson (October 2001 March 2005). D. Mott-Bronson: (June 1998 - September 2002); Democratic Professional Staff Member, House International Relations Committee, Representative McKinney (September 2002 December 2002).

Client expense: $2,450,000 · Firm income: Not reported

Government targets: Administration on Aging, Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Federal Bureau of Investigation (FBI), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Office of Personnel Management (OPM), Pension & Welfare Benefits Administration, SENATE, Treasury, Dept of, White House Office